- Conditions
- High Risk Atherosclerotic Cardiovascular Disease
- Interventions
- Electronic Alert
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,596 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Bridgeport, Connecticut • Greenwich, Connecticut • New Haven, Connecticut
Clinical trials in New Haven, Connecticut
This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in New Haven
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
- Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 889
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 593 more
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Avelumab, Talazoparib, Talazoparib Tosylate
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 325
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Anaheim, California + 257 more
- Conditions
- Type 1 Diabetes
- Interventions
- Virtual home intervention
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 14 Years to 19 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Kidney Transplant; Complications
- Interventions
- Tacrolimus, Extended Release, (Envarsus Xr)
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Physical Performance
- Interventions
- IMU (Inertial Measurement Unit) sensors
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Chronic Low-back Pain
- Interventions
- LY3857210, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 28
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Riverside, California + 23 more
- Conditions
- ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
- Interventions
- PF-06463922, Crizotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 32
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Orange, California + 14 more
- Conditions
- Cluster Headache, Episodic
- Interventions
- Eptinezumab, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 19 more
- Conditions
- Overweight, Obesity
- Interventions
- Formulation A (PF-07081532 20 mg plus 60 mg), Formulation B (PF-07081532 80 mg)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- LY3857210, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 28
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Riverside, California + 23 more
- Conditions
- Healthy
- Interventions
- ARV-471, Rosuvastatin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut